Pharnext Announces Reclassification of Its Historical Investor’s Shares, Strengthening the Position of Core Shareholders
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, was informed of a reclassification of its historical investor’s shares.
2,143,736 shares held by Truffle Capital, co-founder of Pharnext, and representing 19.9% ownership of the company, have just been reclassified to existing shareholders including two core shareholders: Pierre Bastid (+600,000 shares) and Claude Berda (+1,243,736 shares). Truffle Capital states that the funds selling the shares are mutual investment funds that have reached maturity and therefore had a regulatory obligation to exit from their investments and, that other recent funds invested in Pharnext’s Initial Public Offering in July 2016.
The initial lock-up commitments relating to the shares have been assumed in full by their new owners.
After such reclassification, new ownership of Pharnext's shares and voting rights are as follows:
|Founders and employees||1,318,084||12.2%||2,617,684||17.8%|
|Pierre Bastid (Zaka)||2,542,301||23.6%||3,267,901||22.3%|
|Claude Berda (CBLux)||1,632,688||15.1%||1,632,688||11.1%|
Industrials (Galapagos, Ipsen, Mérieux,
|Public (institutionnals and individuals)||3,486,111||32.3%||4,891,511||33.3%|
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several compositions of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, please visit www.pharnext.com
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
Caroline Carmagnol / Margaux Pronost
+33 (0)1 44 54 36 64
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1 212-362-1200
Media Relations (U.S.)
Tony Russo, Ph.D. / Victoria Meissner, M.D.
+1 212-845-4251 / +1 646-942-5627
Investor Relations (France)
Julie Coulot, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FUNDINFO21.3.2018 10:43 | pressemeddelelse
fundinfo Launches New Fund News Service in Cooperation with UBS
NJ-MSD-ANIMAL-HEALTH21.3.2018 07:02 | pressemeddelelse
MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO® Plus (fluralaner plus moxidectin) Spot-on Solution for Cats
GEMALTO21.3.2018 07:02 | pressemeddelelse
Gemalto Unveils Two New Enhanced Security Features for ID Documents
LIAF20.3.2018 19:29 | pressemeddelelse
LIAF: Experts at the European Parlament - E-Cigarettes Are a Potential Game Changer for European Health
MORINAGA-MILK-INDUSTRY20.3.2018 19:02 | pressemeddelelse
Morinaga Milk's New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer's Disease
DEWA20.3.2018 17:12 | pressemeddelelse
Dubai Breaks Ground on World’s Biggest CSP Project
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum